Drug Kinetics – Multimedia

The importance of glucuronidation for metabolism of xenobiotics in humans is illustrated by the abundance and broad tissue distribution of the enzymes, the diversity of substrates and reactions catalyzed, as well as a number of distinctive UGT enzymes and their genetic polymorphisms.

Binding kinetic research is both beneficial and critical for successful drug discovery research. In this eBook, we delve into the role of binding kinetics in pharmacology, methods for measuring kinetic parameters, and applications.

Watch our expert, Maureen Bunger, PhD, explain how our patented manufacturing process ensures that the DonorPlex™ Hepatocytes exhibit improved phenotype reproducibility.

Aldehyde oxidase (AO) enzyme has gained increasing attention in drug development as one of the alternative approaches to reduce P450-mediated drug metabolism liability. However, clinical failure due to poor prediction of AO-mediated clearance is a major hurdle in development of drugs that are AO substrates.

Download this listicle to discover answers to key questions such as: can therapeutic drug monitoring (TDM) be used for all drugs? Which drugs are currently monitored using TDM approaches? What analytical methods are used for TDM?

In this webinar, SEKISUI XenoTech study director Dr. Steven McGreal will cover study design elements and other considerations like timing and characteristics of drugs with high RBC partitioning. He will discuss impacts on PK calculations and provide examples of how RBC partitioning rates can cause errors downstream if not properly investigated early in drug development.

Antibodies are subject to instability issues due to chemical and physical instabilities and these effects can change the pharmacokinetics of the antibody. For this reason, produced antibodies must be thoroughly tested before they can be applied for treatment of patients.

Being able to accurately predict drug–target interactions (DTIs) and drug–target binding affinity (DTBA) is crucial in early drug development and during drug repurposing endeavors. Here, we look at some recent research developments in this space.

Although cytochrome P450 (CYP)-mediated metabolism continues to be of major importance for a large proportion of small molecule new drug candidates, various methods in recent decades have accelerated the development of drug candidates with significant non CYP-mediated metabolism.

Drugs elicit their desired therapeutic effects by interacting with specific disease-related targets. However, to determine exactly how a drug works inside the body it is important to address key questions. What type of drug is being used? How is it being administered? What are the characteristics of the individual taking the drug?